格隆汇9月23日丨中国生物制药(01177.HK)宣布，公司全资附属公司礼新医药科技(上海)有限公司("礼新 医药")自主研发的国家1类创新药LM-2417"NaPi2b/4-1BB双特异性抗体"在中国开展的I期临床试验已顺 利完成首例患者入组，标志着这一创新疗法正式进入临床开发阶段。 本次临床研究为一项注射用LM-2417单药或联合其他抗肿瘤药物在晚期恶性实体肿瘤患者中的安全性、 耐受性、药代动力学特徵以及初步疗效的开放标签、剂量递增和剂量扩展的I/II期临床研究。集团将继 续快速推进项目的临床研究，期待早日为患者带来免疫治疗临床用药新选择。 LM-2417是礼新医药基於其自主研发的条件激活型4-1BB平台开发的一款NaPi2b/4-1BB双抗，能够特异 性结合肿瘤细胞表面的NaPi2b及免疫细胞表面的4-1BB。该机制可实现免疫细胞在肿瘤微环境中的精准 激活，从而增强抗肿瘤效应。与传统4-1BB激动剂不同，LM-2417通过NaPi2b依赖性方式选择性激活4- 1BB信号通路，有望显著降低非特异性免疫激活引发的毒性风险。 临床前数据表明，LM-2417不仅能诱导持久的抗肿瘤免疫记忆，还在与其他免疫治疗药物 ...

Group 1 - The core announcement is about the approval of the drug Remimazolam injection for use in children, expanding its application in anesthesia [1][2] - The drug, developed by the company, is a new class of intravenous anesthetic that was approved for domestic use in December 2020 and has shown significant clinical value, especially in pediatric patients [2][3] - The drug has demonstrated good tolerance and lower pain response at the injection site, making it a safer and more comfortable option for patients requiring anesthesia [2] Group 2 - The company has submitted a New Drug Application (NDA) to the FDA for the product, which was accepted for review in July 2025 [3] - The drug has already received registration certificates for multiple indications, including sedation and anesthesia during non-intubation surgeries and in intensive care settings [2] - The company emphasizes the cardiovascular safety of the drug, supported by comprehensive clinical trials [2]

Core Viewpoint - The approval of the innovative drug "普佑克" (recombinant human urokinase) for treating acute ischemic stroke (AIS) marks a significant breakthrough in China's thrombolytic therapy for stroke, reflecting the country's push for innovation in biomedicine [1][2]. Company Summary - Tian Shi Li Pharmaceutical Group has received approval from the National Medical Products Administration for its innovative drug "普佑克," which is now indicated for AIS treatment, following its previous approval for acute ST-segment elevation myocardial infarction [1]. - The drug has demonstrated a lower risk of bleeding compared to competitors, as evidenced by clinical trials published in reputable medical journals [1]. - The company has 31 innovative drug projects in development, including advancements in cell and gene therapy and bispecific antibodies, with three products recently receiving clinical approval [2]. Industry Summary - The biopharmaceutical industry in China is experiencing unprecedented growth, with a 59% year-on-year increase in the number of innovative drugs approved in the first half of 2025, totaling 43 approvals, of which 93% are domestic innovations [3]. - The integration of Tian Shi Li into China Resources Sanjiu is expected to enhance its capabilities in key therapeutic areas, optimizing its research and development pipeline [3]. - The Chinese government has implemented supportive policies for the development of innovative drugs, creating a favorable environment for the biopharmaceutical sector [3].

Core Viewpoint - Chuangsheng Group-B (06628) has seen a significant stock price increase of over 10%, currently trading at 4.82 HKD, following the announcement of a strategic cooperation agreement with Huajian Medical (01931) regarding the potential tokenization of innovative drug pipeline assets [1] Group 1: Strategic Cooperation - Chuangsheng Group has entered into a strategic cooperation agreement with Huajian Medical to explore the tokenization of its innovative drug pipeline assets [1] - The agreement involves integrating six core innovative drug pipeline assets (TST003, TST005, TST786, TST105, TST106, and TST013) into its U.S. entity [1] - The collaboration aims to utilize Huajian Medical's ETHK global innovative drug intellectual property RWA exchange for potential RWA tokenization [1] Group 2: Funding and Development - If the token issuance is successful, the proceeds will be used to accelerate the clinical and preclinical development of several innovative antibody projects targeting tumors [1] - The Chairman of Chuangsheng Group, Dr. Qian Xueming, emphasized the need for substantial funding in the long and high-risk process of drug development [1] - The partnership with Huajian Medical's on-chain RWA digital platform will provide a new funding channel by allowing the intellectual property of innovative drug pipelines to be packaged into a U.S. SPV for novel financing [1]

Industry Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The Chinese innovative drug industry has established a trend towards global commercialization, supported by a pyramid structure of leading and quality enterprises, indicating strong sustainability in industry development [2]. - The underlying logic of the current cycle is that Chinese innovative drugs possess global competitiveness, shifting from domestic sales to international licensing and commercialization, thus opening up commercial space and maturing the ecosystem [2]. - The focus on differentiated mechanisms or high clinical value "good molecules" remains a core interest for international buyers, with early data being crucial for entering licensing windows [2]. Current Situation - The Chinese innovative drug industry is entering a phase of realization, driven by support from capital markets, policies, and talent [3]. - The industry has developed self-sustaining capabilities through business development (BD) licensing and drug commercialization [3]. - Comprehensive policy support for "true innovation" has been established, enhancing the industry's growth [3]. Future Outlook - Continued collaboration among academia, industry, and research will enhance the output of first-in-class (FIC) molecules, with China becoming one of the most efficient countries in the drug development pathway [4]. - Higher innovation levels are expected to further unlock commercial value, indicating a promising future for the industry [4]. Investment Recommendations - Focus on global blockbuster products: companies such as BeiGene, Kelun-Biotech, Innovent Biologics, and others are highlighted as key players [5]. - Attention to global best-in-class (BIC) potential companies, including EdiGene, Zai Lab, and others, is recommended [5]. - Domestic blockbuster products and asset values of companies like Hengrui Medicine and others are also suggested for consideration [5].

Investment Rating - The report assigns a "Buy" rating for the stock of Tian Shili (600535) based on its potential growth from the newly approved indication for its drug, Pu You Ke [1]. Core Viewpoints - The approval of Pu You Ke for the treatment of acute ischemic stroke is expected to create a second growth curve for the company, leveraging its established commercial framework and clinical evidence [2][3]. - Acute ischemic stroke has a high incidence rate, and Pu You Ke is positioned to meet unmet clinical needs, offering a safer alternative to existing treatments like alteplase [4][5][6]. - The company is committed to innovation, with a robust pipeline of 83 projects, including several promising drugs that could enhance its market position [7][8]. Financial Summary - The projected revenue for the company from 2025 to 2027 is expected to be 86.60 billion, 93.24 billion, and 100.81 billion respectively, with net profits of 11.96 billion, 13.31 billion, and 14.84 billion [10]. - The earnings per share (EPS) are forecasted to be 0.80 yuan, 0.89 yuan, and 0.99 yuan for the same period, with corresponding price-to-earnings (P/E) ratios of 19.62, 17.63, and 15.82 [10].

Group 1 - The company is covered for the first time by Guojin Securities, which gives a "buy" rating and forecasts revenue of 33.41 billion, 37.17 billion, and 41.70 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth of +15.75%, +11.24%, and +12.21% [1] - The net profit attributable to the parent company is projected to be 4.63 billion, 4.75 billion, and 5.28 billion yuan for the same years, with year-on-year growth of +32.17%, +2.75%, and +11.17% [1] - The company has a solid position as a leading pharmaceutical player, with a steady increase in revenue and operating profit, and a significant rise in R&D investment, which accounted for 18.1% of revenue in H1 2025, up from 11.1% in 2020 [1] Group 2 - The company acquired Lixin Pharmaceutical for approximately 500 million USD, enhancing its oncology product pipeline [2] - The drug Anlotinib has been approved for 9 indications, and its combination with PD-1 has shown superior results in head-to-head trials against other treatments [2] - The company aims to license out innovative products as a key strategic goal, with promising candidates in oncology and respiratory fields, potentially generating recurring revenue from business development transactions starting in 2025 [3]

Summary of Key Points from the Conference Call on China's Innovative Drug Industry Industry Overview - The Chinese innovative drug industry is transitioning from a follower to a leader, showcasing significant advantages in R&D efficiency and cost control, particularly in popular technology areas such as bispecific antibodies (双抗) and antibody-drug conjugates (ADC) [1][2][3] - The approval speed of innovative drugs directly impacts market volume and competitive landscape, with early market entry being crucial [1][6] Core Insights and Arguments - **Market Dynamics**: The Chinese innovative drug sector is experiencing a shift in underlying logic, with improved liquidity in the Hong Kong stock market and increased risk appetite expected to boost the pharmaceutical sector, especially innovative drugs [1][8] - **International Recognition**: Chinese innovative drugs are gaining international recognition, exemplified by the $1.25 billion upfront payment for the PD-1 VGF bispecific antibody licensed to Pfizer by 3SBio, marking a significant milestone in outbound business development (BD) transactions [1][9] - **Policy Influence**: Healthcare policies are encouraging differentiated innovation, with diverse payment methods being explored, and the impact of drug price reduction policies being limited [1][4][5] Key Factors Affecting the Industry - **Types of Companies**: The innovative drug sector comprises Big Pharma and Biotech companies, with Big Pharma focusing on commercialization and Biotech emphasizing R&D innovation [1][7] - **Investment Sentiment**: The overall performance of the pharmaceutical sector has been weak from 2020 to 2024 due to investor preference for dividend stocks, but improvements in liquidity and risk appetite in 2025 are expected to enhance the performance of the innovative drug sector [1][8] Challenges and Opportunities - **Global Competition**: As the global source innovation enters a bottleneck, Chinese companies can leverage high efficiency to achieve competitive advantages, particularly in ADC and bispecific antibody fields where they hold significant market shares [1][20][22] - **Market Entry Timing**: The timing of market entry is critical, with first-in-class drugs capturing an average of 45% market share, while subsequent entrants see diminishing returns [1][18] Emerging Trends and Future Directions - **New Drug Development**: The focus on PD-1 bispecific antibodies and ADCs is expected to drive future growth, with several companies poised to launch significant products in the near term [1][31][32] - **Clinical Trial Efficiency**: Chinese companies demonstrate superior enrollment speeds in clinical trials, significantly reducing time and costs compared to international counterparts [1][16] Conclusion - The Chinese innovative drug industry is positioned for substantial growth driven by policy support, international recognition, and advancements in R&D efficiency. The upcoming years are likely to see increased BD activities and successful product launches, contributing to the sector's evolution and competitiveness on a global scale [1][10][32]

Group 1: Product and Market Potential - Puyouke is a first-class biological innovative drug approved under the "Major New Drug Creation" project, now gaining approval for acute ischemic stroke indication, marking its second indication in China [1] - Compared to other thrombolytic drugs, Puyouke has a unique thrombolytic mechanism with lower systemic bleeding risk and high safety, showing a significantly lower rate of symptomatic intracranial hemorrhage in clinical trials [1] - In 2019, there were 3.94 million new stroke cases in China, with ischemic strokes accounting for 2.87 million (72.8%), indicating a growing market for stroke treatment [2] Group 2: Industry Trends and Treatment Rates - The incidence of ischemic stroke in China increased from 117 per 100,000 in 2005 to 145 per 100,000 in 2019, with an annual growth rate of 4-6% [2] - The treatment rates for acute ischemic stroke in China are still low, with intravenous thrombolysis at 5.64% and endovascular treatment at only 1.45% in 2019-2020, suggesting significant room for improvement [2] Group 3: Company Innovation and Pipeline - Tianshili is focused on dual-engine innovation in traditional Chinese medicine and biological drugs, with 31 innovative drugs in its pipeline [3] - The company has made significant progress in both traditional and biological drug sectors, with multiple products in late-stage clinical trials [3] - Following its integration with China Resources Sanjiu, Tianshili aims to become a leading innovative pharmaceutical company in China, with a clear strategy for its research pipeline that has yet to be fully valued by the market [3]

Group 1: Huadong Medicine - Huadong Medicine's subsidiary received FDA approval for the clinical trial of HDM2017, a new antibody-drug conjugate targeting Cadherin17 for advanced malignant solid tumors [1] Group 2: Tianjin Tasly - Tasly's subsidiary received approval for the new indication of Pu You Ke for thrombolytic treatment of acute ischemic stroke, making it the only approved recombinant human urokinase product in China [2] Group 3: Yabao Pharmaceutical - Yabao Pharmaceutical decided to terminate the clinical trial of SY-009 and fully provision for asset impairment of 55.793 million yuan, which will reduce the company's profit for 2025 [3][4] Group 4: Zhixiang Jintai - Zhixiang Jintai signed exclusive cooperation agreements with Kangzhe Pharmaceutical for the commercialization of GR2001 and GR1801 monoclonal antibodies, with expected payments totaling approximately 510 million yuan [4] Group 5: Lepu Medical - Lepu Medical entered a strategic partnership with Hanhai Information to jointly develop the medical aesthetics business, aiming to enhance sales channels and improve performance amid industry competition [5]